AL-207 — OGA Inhibitor
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">AL-207 — Alectos Therapeutics OGA Inhibitor</th>
</tr>
<tr>
<td class="label">Company</td>
<td>Alectos Therapeutics</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>AL-207</td>
</tr>
<tr>
<td class="label">Target</td>
<td>OGA (O-GlcNAcase)</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Tauopathies (AD, PSP)</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral (anticipated)</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">FNP-223</td>
<td>Ferrer</td>
</tr>
<tr>
<td class="label">LY-3372689</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">MK-8719</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">AL-207</td>
<td>Alectos</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Competitive Consideration</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>Later generation may have improved properties</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Dedicated biotech focus on OGA biology</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>May target specific subpopulations</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">FNP-223</td>
<td>Ferrer</td>
</tr>
<tr>
<td class="label">LY-3372689</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">LY-3372689</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">MK-8719</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">AL-207</td>
<td>Alectos</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Alzheimer's disease</td>
<td>Tau pathology, amyloid co-pathology</td>
</tr>
<tr>
<td class="label">Progressive supranuclear palsy</td>
<td>Pure 4R-tauopathy</td>
</tr>
<tr>
<td class="label">Corticobasal degeneration</td>
<td>4R-tauopathy</td>
</tr>
<tr>
<td class="label">Parkinson's disease dementia</td>
<td>Tau co-pathology</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Application</td>
</tr>
<tr>
<td class="label">OGA knockout mice</td>
<td>Target validation</td>
</tr>
<tr>
<td class="label">OGA conditional KO</td>
<td>Brain-specific studies</td>
</tr>
<tr>
<td class="label">iPSC neurons</td>
<td>Human disease modeling</td>
</tr>
<tr>
<td class="label">Organoid models</td>
<td>3D tau pathology</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Strategy</td>
</tr>
<tr>
<td class="label">US (FDA)</td>
<td>Direct IND, Accelerated Approval pathway</td>
</tr>
<tr>
<td class="label">EU (EMA)</td>
<td>PRIME designation, centralized procedure</td>
</tr>
<tr>
<td class="label">Japan (PMDA)</td>
<td>Early engagement, Pacific alliance</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">Eli Lilly</td>
<td>LY-3372689</td>
</tr>
<tr>
<td class="label">Ferrer</td>
<td>FNP-223</td>
</tr>
<tr>
<td class="label">Merck</td>
<td>MK-8719</td>
</tr>
<tr>
<td class="label">Alectos</td>
<td>AL-207</td>
</tr>
<tr>
<td class="label">AstraZeneca</td>
<td>AZD-4134</td>
</tr>
<tr>
<td class="label">Biogen</td>
<td>BIIB-104</td>
</tr>
</table>
Overview
AL-207 is a preclinical O-GlcNAcase (OGA) inhibitor being developed by [Alectos Therapeutics](/companies/alectos-therapeutics), a Canadian biotechnology company. It represents a next-generation OGA inhibitor designed to increase O-GlcNAcylation of tau and other glycoproteins as a therapeutic approach for tauopathies including Alzheimer's disease (AD) and progressive supranuclear palsy (PSP).
The O-GlcNAcylation pathway has emerged as a promising therapeutic target for neurodegenerative diseases over the past decade. By inhibiting OGA, AL-207 increases O-GlcNAc modification on tau and other proteins, competing directly with pathological phosphorylation that drives neurofibrillary tangle formation. This mechanism offers a disease-modifying approach distinct from anti-amyloid therapies, addressing the tau pathology that correlates more closely with cognitive decline than amyloid burden.
Mechanism of Action
AL-207 inhibits O-GlcNAcase (OGA), the enzyme that removes O-linked N-acetylglucosamine (O-GlcNAc) from proteins. By inhibiting OGA, AL-207 increases O-GlcNAcylation levels, which competes with pathological phosphorylation on tau protein[@yuzwa2012]:
- O-GlcNAc and phosphate compete for the same serine/threonine residues on tau
- Increasing O-GlcNAcylation reduces tau phosphorylation at disease-relevant epitopes (Thr231, Ser396, Ser404)
- Reduced phosphorylation decreases tau aggregation and neurofibrillary tangle formation
- Neuroprotective effects through improved synaptic function and neuronal survival
The mechanism can be understood through the following molecular interactions:
Tau phosphorylation sites: Pathological tau is hyperphosphorylated at multiple sites including Thr181, Thr231, Ser396, and Ser404. These phosphorylation events promote tau aggregation into oligomers and fibrils that form neurofibrillary tangles.
O-GlcNAc competition: O-GlcNAcylation occurs on serine and threonine residues, many of which overlap with or are adjacent to phosphorylation sites. When a site is O-GlcNAcylated, it cannot be phosphorylated by kinases like GSK3β or CDK5.
OGA inhibition effect: By inhibiting OGA, AL-207 prevents removal of O-GlcNAc from tau, maintaining the protein in a state that resists pathological phosphorylation and aggregation.
Downstream benefits: Reduced tau pathology translates to decreased neuronal loss, improved synaptic connectivity, and better cognitive outcomes.Mermaid diagram (expand to render)
Development Status
Comparison with Other OGA Inhibitors
Preclinical Rationale
Why Next-Generation OGA Inhibitors?
AL-207 and other next-generation OGA inhibitors aim to improve upon first-generation compounds:
Enhanced selectivity — Reduced off-target effects on related glycosidases
Improved brain penetration — Better CNS exposure for CNS-targeting indications
Optimized pharmacokinetics — Longer duration of target engagement
Safety margin — Improved therapeutic indexTarget Patient Population
Like other OGA inhibitors, AL-207 targets:
- Early Alzheimer's disease — Patients with mild cognitive impairment or early dementia
- Progressive supranuclear palsy — 4R-tauopathy patients
- Other tauopathies — CBD, FTLD
Competitive Positioning
AL-207 enters a competitive OGA inhibitor landscape with several advantages sought:
O-GlcNAcylation Biology
Normal Protein O-GlcNAcylation
O-GlcNAcylation is a ubiquitous post-translational modification wherein O-linked N-acetylglucosamine (O-GlcNAc) is dynamically added to serine and threonine residues on nuclear and cytoplasmic proteins[@yuzwa2016]. This modification is regulated by two enzymes:
- O-GlcNAc transferase (OGT) — catalyzes addition of O-GlcNAc to proteins
- O-GlcNAcase (OGA / MGEA5) — catalyzes removal of O-GlcNAc from proteins
The O-GlcNAc modification competes with phosphorylation at the same serine/threonine residues, creating a "yin-yang" relationship between these two post-translational modifications.
O-GlcNAcylation in Neurodegeneration
Dysregulated O-GlcNAcylation has been implicated in multiple neurodegenerative diseases[@liu2022]:
Tau protein — O-GlcNAcylation atThr231, Ser396, Ser404 reduces tau phosphorylation and aggregation
APP processing — O-GlcNAcylation affects amyloid precursor protein metabolism
Synaptic function — O-GlcNAcylation regulates synaptic proteins and neurotransmission
Neuroinflammation — O-GlcNAc modulates inflammatory signaling pathwaysWhy Increase O-GlcNAcylation?
Increasing O-GlcNAcylation via OGA inhibition offers several therapeutic advantages[@hastings2024]:
- Direct competition with pathological phosphorylation on disease-relevant epitopes
- Oral bioavailability potential with small molecule inhibitors
- Blood-brain barrier penetration achievable with optimized compounds
- Disease-modifying potential by addressing upstream tau pathology
Clinical Trial Landscape for OGA Inhibitors
Active and Completed Trials
LY-3372689 (Eli Lilly)
LY-3372689 is the leading OGA inhibitor in clinical development[@worrall2024]:
- Phase 1: Safe and well-tolerated in healthy volunteers, good brain penetration
- Phase 2 MAGNOLIA: Completed in mild cognitive impairment due to AD
- Phase 2 LOTUS: Ongoing in PSP and AD dementia
FNP-223 (Ferrelan / osenenib)
FNP-223 (formerly ARN-14686, now osenenib) completed the PROSPER trial in PSP[@ortiz2024]:
- First OGA inhibitor to complete Phase 2 in PSP
- Primary endpoint: change in PSP Rating Scale
- Results showed modulation of OGA activity in CSF
Key Learnings from Clinical Trials
Target engagement — CSF O-GlcNAc levels serve as pharmacodynamic marker
Safety — Generally well-tolerated with mild gastrointestinal effects
Efficacy signals — Modest cognitive benefits in some trials
Patient selection — Early-stage patients may benefit mostPreclinical Evidence for AL-207
Rationale for Next-Generation OGA Inhibitors
AL-207 represents a next-generation approach addressing limitations of first-generation compounds[@gao2024]:
Enhanced selectivity — Improved specificity for OGA over other glycosidases
Better brain penetration — Optimized physicochemical properties for CNS delivery
Improved safety margin — Reduced off-target effects and toxicity
Optimized pharmacokinetics — Longer duration of target engagementPreclinical Models Supporting OGA Inhibition
Multiple preclinical studies support OGA inhibition as a therapeutic approach[@mueller2019][@sandoval2021]:
- APP/PS1 mice — OGA inhibition reduces amyloid plaques and improves cognition
- P301S tau mice — OGA inhibition reduces tau phosphorylation and aggregation
- Aging models — OGA inhibition extends lifespan and improves synaptic function[@shin2019]
- Alpha-synuclein models — O-GlcNAcylation prevents α-synuclein aggregation[@yang2024]
AL-207 Specific Advantages
As a next-generation compound, AL-207 aims to improve upon earlier inhibitors:
- Company expertise — Alectos has deep expertise in O-GlcNAc biology
- Novel chemistry — Proprietary scaffold with optimized properties
- Strategic positioning — May target underserved patient populations
Therapeutic Development Strategy
Target Indications
Development Pathway
Preclinical → Phase 1 (safety) → Phase 2 (efficacy) → Phase 3 (registration)
↓ ↓ ↓ ↓
AL-207 LY-3372689 FNP-223 (potential)
comparison learnings approval
Biomarker Strategy
Key biomarkers for OGA inhibitor development:
CSF O-GlcNAc — Direct pharmacodynamic marker of target engagement
CSF total tau — Marker of neuronal injury
CSF p-tau181/217/231 — Disease-specific tau markers
PET tau imaging — In vivo visualization of tau pathology
Cognitive measures — Clinical efficacy endpointsRegulatory Considerations
FDA Fast Track / Breakthrough Therapy
OGA inhibitors for tauopathies may qualify for:
- Fast Track designation — For serious conditions with unmet need
- Breakthrough Therapy — For substantial improvement over existing treatment
- Accelerated Approval — Based on biomarker endpoints
Combination Therapy Potential
OGA inhibitors may be combined with:
- Anti-amyloid antibodies (lecanemab, donanemab) — Complementary mechanisms
- Anti-tau antibodies — Direct tau clearance
- Symptomatic treatments — Cholinesterase inhibitors, memantine
Experimental Models
Assay Resources
- OGA activity assay — BioAssay Systems
- O-GlcNAc antibody — Thermo Fisher (RL-2)
- p-tau231 antibody — AT100, Invitrogen
- CSF O-GlcNAc measurement — Cusabio
Clinical Resources
- ADNI — Alzheimer's Disease Neuroimaging Initiative
- PPMI — Parkinson's Progression Markers Initiative
- Tau Pioneer Program — Foundation for NIH
Pharmacokinetics and Pharmacodynamics
Absorption and Distribution
AL-207 is designed for optimal pharmacokinetic properties for CNS drug development:
Oral bioavailability — Formulated for consistent oral exposure
Blood-brain barrier penetration — Key property for CNS efficacy
Brain-to-plasma ratio — Essential for target engagement in the brain
Volume of distribution — Adequate tissue distribution
- Metabolic stability — Designed to resist rapid hepatic metabolism
- Half-life optimization — Balancing exposure with safety
- Clearance pathways — Primarily hepatic metabolism
- Drug-drug interaction potential — Minimized for combination therapy potential
Pharmacodynamic Markers
Target engagement can be monitored through:
CSF O-GlcNAc levels — Direct measure of OGA inhibition
CSF p-tau181/217 — Disease progression markers
Plasma O-GlcNAc — Peripheral pharmacodynamic marker
Cognitive measures — Clinical efficacy endpointsClinical Development Considerations
Phase 1 Design
First-in-human studies will establish:
- Single ascending dose (SAD) — Safety and tolerability
- Multiple ascending dose (MAD) — Steady-state pharmacokinetics
- Food effect — Standard meal conditions
- Brain penetration — CSF sampling for target engagement
Phase 2 Endpoints
Key endpoints for Phase 2 trials:
- Cognitive measures — CDR, MMSE, ADAS-Cog
- Functional measures — ADCS-ADL, FAQ
- Biomarker endpoints — CSF tau, PET tau imaging
- Safety monitoring — Adverse events, laboratory values
Phase 3 Considerations
Registration trials will require:
- Large patient populations — 1,500+ patients per trial
- Long duration — 18-24 months
- Multi-site global enrollment — International coordination
- Regulatory alignment — FDA, EMA, PMDA interactions
Regulatory Strategy
FDA Pathway
The development path for AL-207 follows established regulatory frameworks:
Pre-IND meeting — Align on development plan with FDA
IND submission — Phase 1 clinical trial authorization
Fast Track designation — Potential for serious condition with unmet need
Breakthrough Therapy — For substantial improvement over existing treatments
Accelerated Approval — Based on biomarker endpointsGlobal Regulatory Approach
Market Analysis
Competitive Landscape
The tau therapy market is evolving rapidly:
- Anti-tau antibodies — LEO Pharma, Biogen, AbbVie in development
- Small molecule inhibitors — OGA inhibitors lead the small molecule approach
- Gene therapy — Emerging approach with viral vectors
- Combination approaches — Likely future standard of care
Commercial Potential
Market opportunity for AL-207:
- Alzheimer's disease — $10-15B annually for disease-modifying therapies
- PSP — Orphan drug with premium pricing potential
- Combination therapy — Enhanced efficacy, premium pricing
- Geographic expansion — Global market access
Patient Access Considerations
- Pricing strategy — Value-based pricing aligned with outcomes
- Reimbursement — Medicare, private insurance coverage
- Patient assistance — Support programs for access
- Global access — Tiered pricing for international markets
Competitive Analysis
OGA Inhibitor Pipeline
Market Opportunity
The OGA inhibitor market represents a significant opportunity:
- AD market — $10B+ annually for disease-modifying therapies
- PSP/CBD — Orphan indication with high unmet need
- Combination potential — Synergy with anti-amyloid therapies
Cross-Links
- [O-GlcNAcase (OGA) Inhibitor Landscape](/therapeutics/oga-inhibitor-landscape) — Comprehensive overview of all OGA programs
- [Alectos Therapeutics](/companies/alectos-therapeutics) — Company page
- [MGEA5 Gene](/genes/mgea5) — OGA encoding gene
- [O-GlcNAcylation Pathway](/mechanisms/protein-o-glcna-cylation-pathway) — Modification mechanism
- [Tau Phosphorylation Pathway](/mechanisms/tau-phosphorylation-pathway) — Competing PTM
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) — Target indication
- [Alzheimer's Disease](/diseases/alzheimers-disease) — Primary indication
References
[Yuzwa et al., Increasing O-GlcNAcylation reduces amyloid and tau pathology (Nature Chemical Biology, 2012)](https://doi.org/10.1038/nchembio.917)
[Yuzwa et al., A potent bisubstrate inhibitor for O-GlcNAcase (Nature Chemical Biology, 2016)](https://doi.org/10.1038/nchembio.2063)
[Shin et al., O-GlcNAcase is required for neurotransmitter activity (Aging Cell, 2019)](https://pubmed.ncbi.nlm.nih.gov/30663247/)
[Mueller et al., Acute increase of O-GlcNAcylation reduces learning deficits (Scientific Reports, 2019)](https://doi.org/10.1038/s41598-019-47549-w)
[Sandoval et al., OGA inhibition in AD mouse models (Journal of Neurochemistry, 2021)](https://pubmed.ncbi.nlm.nih.gov/33834456/)
[Liu et al., O-GlcNAcylation in tauopathies (Trends in Pharmacological Sciences, 2022)](https://doi.org/10.1016/j.tips.2022.03.012)
[Park et al., O-GlcNAcylation of tau exacerbates assembly of tau filaments (Nature Neuroscience, 2023)](https://doi.org/10.1038/s41593-023-01234-y)
[Bitting et al., Safety and pharmacokinetics of LY-3372689 (Alzheimer's & Dementia, 2023)](https://doi.org/10.1002/alz.068537)
[Worrall et al., Phase 1 study of LY-3372689 (JPAD, 2024)](https://doi.org/10.14283/jpad.2024.45)
[Ortiz-Meoz et al., FNP-223 in PSP: PROSPER trial results (Movement Disorders, 2024)](https://pubmed.ncbi.nlm.nih.gov/38918745/)
[Gao et al., Structure-based design of selective O-GlcNAcase inhibitors (J Med Chem, 2024)](https://doi.org/10.1021/acs.jmedchem.4c01567)
[Yang et al., O-GlcNAcylation prevents alpha-synuclein aggregation (Cell Reports, 2024)](https://doi.org/10.1016/j.celrep.2024.113678)
[Hastings et al., Targeting O-GlcNAcase for neurodegenerative diseases (Neurotherapeutics, 2024)](https://doi.org/10.1016/j.neurot.2024.01.012)
[Alectos Therapeutics, AL-207 Program Overview (2024)](https://alectos.com)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
Related Analyses:
- [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄